Should you be adding abiraterone acetate to your ADT?

The data previously reported from the STAMPEDE trial and the LATITUDE trial over the past couple of days were from men newly diagnosed with high-risk and/or metastatic forms of prostate cancer, but … READ MORE …

ADT + radiation therapy in men with high-risk prostate cancer

So one of the more important papers that will be presented at the ASCO meeting in Chicago today will give us the 10-year results of the Canadian PCS IV trial. … READ MORE …

“How are you feeling?” can be an important question for men on ADT

At the upcoming meeting of the American Society for Clincial Oncology (ASCO) meeting in Chicago, Dr. Alicia Morgans of Vanderbilt University will be speaking about the physical and cognitive effects of systemic therapy in older men with prostate cancer. … READ MORE …

Yes guys … exercise is good for men on ADT!

It has long been understood that taking regular exercise can be helpful in management of risk for fatigue among men being treated with androgen deprivation therapy (ADT) for prostate cancer — whatever the stage of prostate cancer that the patient is being treated for. … READ MORE …

Real care beyond medical treatment, and impact on quality of life

A small, recent pilot study in Geneva, Switzerland, has shown that radiation therapy (RT) + androgen deprivation therapy (ADT) can be given safely to frail patients with non-metastatic, locally advanced or aggressive, intermediate prostate cancer, if and when a multidisciplinary care program is implemented to help such frail patients to limit risk for and manage predictable side effects. … READ MORE …

Serious pneumonia: yet another potential complication of treatment with ADT

It has been known for some time that androgen deprivation therapy (ADT) may increase risk for pneumonia because, normally, androgen levels have effects on how well the immune system works and on the health of lung tissue. … READ MORE …

Testosterone levels in patients on androgen deprivation therapy

For the past 40 years, the formal level of “effectiveness” of androgen deprivation therapy (ADT, also known as “hormone” therapy) for men treated for high-risk, progressive, and/or metastatic prostate cancer has been a serum testosterone level of < 50 ng/dl (equivalent to < 1.7 nmol/l). However, … READ MORE …